Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 mars 2018 16h05 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update

SANTA MONICA, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
12 févr. 2018 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Based on FDA Feedback, Opiant Intends to Pursue 505 (b)(2) Development Pathway Opiant Anticipates Submitting an NDA for this Product Candidate in 2020 SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE...
08 févr. 2018 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose

SANTA MONICA, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
02 janv. 2018 16h01 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants

SANTA MONICA, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
20 déc. 2017 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose

Opiant Expects to Receive 90% of NARCAN Sales-Related Royalty and Milestone Payments, Going Forward SANTA MONICA, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”)...
19 déc. 2017 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017

SANTA MONICA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
18 déc. 2017 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine

Data Published Online in Journal of Medicinal Chemistry Company Evaluating Potential Clinical Program for OPNT005 SANTA MONICA, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Opiant...
04 déc. 2017 16h05 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results

SANTA MONICA, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
13 oct. 2017 07h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

SANTA MONICA, Calif, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
02 oct. 2017 07h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment

SANTA MONICA, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced a collaboration to explore...

Page précédente

Page suivante